Group 1: Company Performance and Financials - The company's contract liabilities at the end of Q1 amounted to 158 million yuan, representing a 59.70% increase compared to the end of the previous year, indicating a strong order backlog that supports a recovery in the main business by 2025 [1] - In Q1 2025, the company invested 9.156 million yuan in R&D, accounting for 22.79% of its revenue, which is an increase of 9.48 percentage points year-on-year [4] - The company achieved overseas revenue of 17.6264 million yuan in 2024, a year-on-year increase of 39.38%, with a gross margin of 44.90% [5] Group 2: Industry Trends and Opportunities - The innovative drug sector is leading a resurgence in the pharmaceutical industry, with Chinese pharmaceutical companies completing 33 license-out transactions in Q1 2025, totaling 36.633 billion USD, a year-on-year increase of approximately 258% [2] - The medical device industry is experiencing a structural transformation, driven by an aging population and increasing healthcare expenditures, which provide significant growth opportunities for the medical consumables market [2] - The global market for intelligent medical equipment is projected to reach 474 billion USD by 2032, indicating a revolutionary change in the healthcare sector [3] Group 3: Technological Advancements and Collaborations - The company is recognized as a leader in the development of intelligent medical equipment, with a focus on continuous R&D investment, which reached 40.4119 million yuan in 2024, a 21.81% increase year-on-year [4] - The company has established strategic partnerships with industry leaders, developing advanced automated production lines that incorporate cutting-edge technologies, thus overcoming long-standing technological bottlenecks [5] - The company is actively expanding its international market presence through various promotional channels, enhancing its visibility and influence in the global market [5] Group 4: Strategic Initiatives and Future Outlook - The actual controller of the company has shown confidence in its long-term development by increasing their shareholding by 49,230 shares, approximately 0.2962% of the total share capital [6] - Since the implementation of share repurchase in September 2024, the company has repurchased 2.5926 million shares, accounting for 1.5597% of the total share capital, with a total repurchase amount of approximately 29.1566 million yuan [7] - The company aims to enhance its production and R&D capabilities while deepening its business layout in the medical consumables sector, aligning with the rapid development of the intelligent equipment industry in China [7]